Executive Interview – Futura Medical

Executive Interview – Futura Medical

The next 12 months should mark the defining events in Futura Medical’s journey towards sustainable profitability. Futura Medical operates with a low fixed-cost base, seeking to outsource most major operations (such as conducting clinical trials, preparing regulatory submissions, formulation and stability testing) and using specialist contractors as appropriate. This ‘virtual’ approach is particularly suitable for a small development player, allowing spending to be tightly controlled with cash outflows occurring only when really needed. With a cash burn of around £2m pa, Futura Medical should be funded through to profitability. The recent £14m placing allows a material acceleration of new product development, notably the pain relief gel portfolio.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.